SCHEMBL1254751

SCHEMBL1254751

CC(C)(C)[SiH2]c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.36
ALDH1A1 P00352 3/20 0.33
TAAR1 Q96RJ0 2/20 0.33
LMNA P02545 2/20 0.33
TSHR P16473 1/20 0.33
ALOX12 P18054 1/20 0.33
ACHE P22303 1/20 0.33
ALOX15 P16050 1/20 0.33
SLC6A2 P23975 1/20 0.33
ESR1 P03372 2/20 0.32
ESR2 Q92731 2/20 0.32
CYP3A4 P08684 1/20 0.32
MAPT P10636 2/20 0.32
HPGD P15428 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MGLL Q99685 1/20 0.32
HSD17B10 Q99714 1/20 0.32
CYP2D6 P10635 1/20 0.31
KMT2A Q03164 1/20 0.31
KCNN4 O15554 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethane SCHEMBL8430515 0.97 MAPK1 (0.35) MAPK1ALDH1A1TAAR1LMNATSHR
SCHEMBL704267 0.84
SCHEMBL21490665 0.79 ALDH1A1 (0.54) MAPK1ALDH1A1LMNATSHRALOX12
SCHEMBL3318941 0.78 ALDH1A1 (0.36) MAPK1ALDH1A1TAAR1LMNATSHR
SCHEMBL7033571 0.78 MAPK1 (0.33) MAPK1ALDH1A1TAAR1LMNATSHR
SCHEMBL5364566 0.78 TAAR1 (0.41) MAPK1ALDH1A1TAAR1LMNATSHR
SCHEMBL3063901 0.74 MAPK1 (0.36) MAPK1ALDH1A1ALOX15KCNN4
SCHEMBL15147452 0.74 RIPK1 (0.35) MAPK1ALDH1A1TAAR1LMNATSHR
SCHEMBL2103073 0.72 TSHR (0.33) MAPK1TSHRMAPT
SCHEMBL2272708 0.72 TAAR1 (0.32) MAPK1TAAR1LMNASLC6A2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220169673-A1 LIPIDIC ANALOGS OF ANTI-CANCER STEM CELL AGENT VIRGINIA COMMONWEALTH UNIVERSITY 2022-06-02 US claimed
EP-3934642-A1 LIPIDIC ANALOGS OF ANTI-CANCER STEM CELL AGENT Virginia Commonwealth University (US) 2022-01-12 EP claimed
WO-2012151094-A2 COMPOSITE MATERIALS FOR BATTERY APPLICATIONS UCHICAGO ARGONNE, LLC (US) 2012-11-08 WO claimed
US-20120282527-A1 COMPOSITE MATERIALS FOR BATTERY APPLICATIONS UCHICAGO ARGONNE, LLC 2012-11-08 US claimed
US-6936537-B2 Methods for forming low-k dielectric films THE BOC GROUP, INC. (US) 2005-08-30 US claimed
US-6649540-B2 Applying on semiconductor or integrated circuit surface substituted organosilane compound precursor, wherein precursor reacts with and deposits on surface and dielectric film THE BOC GROUP, INC. 2003-11-18 US claimed
EP-1271634-A2 Methods for forming low-K dielectric films THE BOC GROUP, INC. (US) 2003-01-02 EP claimed
US-20020192980-A1 Methods for forming low-k dielectric films BOC GROUP, INC., THE 2002-12-19 US claimed
US-20020076944-A1 Organosilane CVD precursors and their use for making organosilane polymer low-k dielectric film BOC GROUP, INC., THE 2002-06-20 US claimed
EP-0409399-B1 3-keto HMG-COA reductase inhibitors MERCK & CO INC (US) 1996-03-13 EP claimed
EP-0313353-B1 MORPHOLINYL SILANES AND USE FOR CONTROL OF PLANT DISEASES CAUSED BY FUNGI DOWELANCO (US) 1992-06-17 EP claimed
US-5041562-A Anticholesterol agents; therapy for arteriosclerosis MERCK & CO., INC. (US) 1991-08-20 US claimed
EP-0313353-A1 Morpholinyl silanes and use for control of plant diseases caused by fungi DOWELANCO (US) 1989-04-26 EP claimed
JP-4342600-A None JP disclosed
JP-8165301-A None JP disclosed
JP-10304889-A None JP disclosed
EP-0551771-A2 Process for producing polysilanes NIPPON OIL CO. LTD. (JP) 1993-07-21 EP disclosed
JP-H04342600-A INTERMEDIATE FOR SYNTHESIZING HCG SUGAR CHAIN TOWA KASEI KOGYO KK 1992-11-30 JP disclosed
US-4839388-A ANTIULCER AGENTS; CIRCULATION AMELIORATORS MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) 1989-06-13 US disclosed
EP-0236510-A1 PROSTACYCLINS AND DRUGS CONTAINING THE SAME MITSUBISHI KASEI CORPORATION (JP) 1987-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169673-A1 LIPIDIC ANALOGS OF ANTI-CANCER STEM CELL AGENT SREBF1, SREBF2, CYP46A1 MAPK1 2370/4885ALDH1A1 493/4885TAAR1 4872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.